CYP2D6 and Plasmodium vivax malaria: Clinical and laboratory evidence suggest that the efficacy of PQ may depend on genetic variation in CYP2D6; vivax malaria relapses following PQ treatment have predominantly been observed in patients carrying CYP2D6 decreased function alleles and nonfunctional alleles in various combinations giving rise to IM and PM phenotypes [20,28–31].